Yimam Mesfin, Lee Young-Chul, Jiao Ping, Hong Mei, Nam Jeong-Bum, Brownell Lidia, Hyun Eujin, Jia Qi
Unigen, Inc., 3005 1 Ave., Seattle, WA 98121, USA.
Unigen, Inc. #450-86, Maebong-Ro, Dongnam-Gu, Cheonan-Si, Chungnam 330-863, Korea.
Pharmacognosy Res. 2016 Jul-Sep;8(3):186-92. doi: 10.4103/0974-8490.182918.
Pain, one of the cardinal signs of inflammation, is the most common clinical manifestations of arthritis. Conventional pain relief therapy heavily relies on the use of prescription and over the counter nonsteroidal anti-inflammatory drugs as the first line of defense where their long-term usage causes deleterious gastrointestinal and cardiovascular-related side-effects. Hence, there is an equivocal need for evidence-based safer and efficacious alternatives from natural sources to overcome the most prominent and disabling symptoms of arthritis.
Carrageenan-induced rat paw edema and abdominal constriction (writhing's) assays in mouse were used to evaluate the anti-inflammatory and analgesic effects of UP1306, a composition that contains a standardized blend of extracts from the heartwood of Acacia catechu and the root bark of Morus alba administered orally at dose ranges of 100-300 mg/kg. Cyclooxygenase (COX) and lipoxygenase (LOX) inhibition assays were carried out to determine the IC50 of Acacia and Morus extracts. The merit of combining these two extracts was also assessed.
Statistically significant improvement in pain resistance and suppression of edema were observed in animals treated with UP1306, when compared to vehicle-treated diseased rats and mice. Results from the high dose of UP1306 (300 mg/kg) were similar to those achieved by ibuprofen treatment at a dose of 200 mg/kg in early hours of treatment. In vitro, UP1306 showed dose-dependent inhibition of the enzymatic activities of COX and LO with IC50 values of 20.9 μg/mL, 49.2 μg/mL, and 11.1 μg/mL in COX-1, COX-2, and 5'-LO, respectively.
These data suggest that UP1306, analgesic, and anti-inflammatory agent of botanical origin with dual COX-LO inhibition activity, could potentially be used to alleviate symptom associated to osteoarthritis.
Pain is the most common clinical manifestations of arthritisCarrageenan-induced rat paw edema and abdominal constriction (writhing's) assays in mouse are among the widely used models to evaluate the anti-inflammatory and analgesic effects of nutraceuticalsCyclooxygenase and lipoxygenase (LO) inhibition assays were carried out to determine the IC50 of Acacia and Morus extracts.Efficacy of UP1306, a composition containing a blend of two standardized extracts from the heartwood of Acacia catechu and root bark of Morus alba, was evaluated in the above models.UP1306 demonstrated its enhanced significance by improving the major cardinal signs of arthritis in vivo and inflammation markers in vitro.UP1306 could potentially be considered as a dietary supplement product for the management of arthritis.
疼痛是炎症的主要症状之一,是关节炎最常见的临床表现。传统的疼痛缓解疗法严重依赖使用处方和非处方非甾体抗炎药作为一线防御手段,但其长期使用会导致有害的胃肠道和心血管相关副作用。因此,迫切需要从天然来源获取基于证据的更安全、有效的替代方案,以克服关节炎最突出和致残的症状。
采用角叉菜胶诱导的大鼠足爪水肿和小鼠腹部收缩(扭体)试验,评估UP1306的抗炎和镇痛作用。UP1306是一种组合物,包含儿茶心材和桑白皮的标准化提取物混合物,以100 - 300 mg/kg的剂量范围口服给药。进行环氧化酶(COX)和脂氧合酶(LOX)抑制试验以确定儿茶和桑的提取物的半数抑制浓度(IC50)。还评估了将这两种提取物组合的优点。
与赋形剂处理的患病大鼠和小鼠相比,用UP1306处理的动物在疼痛抵抗和水肿抑制方面有统计学上的显著改善。高剂量UP1306(300 mg/kg)的结果与在治疗早期200 mg/kg剂量的布洛芬治疗所取得的结果相似。在体外,UP1306显示出对COX和LO酶活性的剂量依赖性抑制,在COX - 1、COX - 2和5'-LO中的IC50值分别为20.9 μg/mL、49.2 μg/mL和11.1 μg/mL。
这些数据表明,UP1306是一种具有双重COX - LO抑制活性的植物源镇痛和抗炎剂,可能可用于缓解与骨关节炎相关的症状。
疼痛是关节炎最常见的临床表现。角叉菜胶诱导的大鼠足爪水肿和小鼠腹部收缩(扭体)试验是广泛用于评估营养保健品抗炎和镇痛作用的模型之一。进行环氧化酶和脂氧合酶(LO)抑制试验以确定儿茶和桑的提取物的IC50。在上述模型中评估了UP1306的功效,UP1306是一种包含儿茶心材和桑白皮两种标准化提取物混合物的组合物。UP1306通过改善体内关节炎的主要症状和体外炎症标志物,显示出其增强的重要性。UP1306可能可被视为用于管理关节炎的膳食补充产品。